Marco Vecchia

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi.

Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi.

Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom.

Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

Chiesi Hellas Pharmaceuticals SA provides research, development and sale of medicinal products. It offers solutions for therapeutic areas such as respiratory, cardiovascular, musculoskeletal, inflammation and neonatology. The company produces respiratory dosage forms such as metered-dose inhalers and sterile unit dose vials for nebulisation. It offers solutions for the treatment of asthma and chronic obstructive pulmonary disease. The company is headquartered in Vrilissa, Greece.

Chiesi Pharmaceuticals BV provides research, development and sale of medical products. It offers solutions for therapeutic areas such as respiratory, cardiovascular, musculoskeletal, inflammation and neonatology. The company is headquartered in Rijswijk, the Netherlands.

Chiesi España SA manufactures and distributes pharmaceutical products. It offers solutions for therapeutic areas such as respiratory, cardiovascular, musculoskeletal, inflammation, and neonatology. The firm produces respiratory dosage forms such as metered-dose inhalers and sterile unit dose vials for nebulisation. It also provides solutions for the treatment of asthma and chronic obstructive pulmonary diseases. The company is headquartered in Barcelona, Spain.

Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom.